Efficacy and Safely of a Topical Gel Formulation of Recombinant Human Platelet-Derived Growth Factor-BB (Becaplermin) in Patients With Chronic Neuropathic Diabetic Ulcers: A phase III randomized placebo-controlled double-blind study

  title={Efficacy and Safely of a Topical Gel Formulation of Recombinant Human Platelet-Derived Growth Factor-BB (Becaplermin) in Patients With Chronic Neuropathic Diabetic Ulcers: A phase III randomized placebo-controlled double-blind study},
  author={T. Jeffery Wieman and Janice M. Smiell and Youping Su},
  journal={Diabetes Care},
  pages={822 - 827}
OBJECTIVE To compare the efficacy and safety of topically applied recombinant human platelet-derived growth factor-BB (rhPDGF-BB) (becaplermin) with placebo gel in patients with chronic diabetic neuropathic ulcers of the lower extremities. RESEARCH DESIGN AND METHODS This multicenter double-blind placebo-controlled phase 111 trial included 382 patients with type 1 or type 2 diabetes and chronic ulcers of at least 8 weeks' duration. After sharp debridement of the ulcer, patients were randomized… 

Figures and Tables from this paper

Recombinant human platelet‐derived growth factor‐BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open‐label clinical evaluation of efficacy
  • J. Embil, Kimberly M. Papp, C. Lau
  • Medicine
    Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
  • 2000
Results of this study further confirm the efficacy and safety of becaplermin gel for the treatment of lower extremity diabetic ulcers.
Efficacy of topical recombinant human platelet derived growth factor on wound healing in patients with chronic diabetic lower limb ulcers
This study did not show any statistically significant improvement in ulcer healing rates after the use of topically applied rhPDGF and was conducted to evaluate its efficacy in the treatment of diabetic foot ulcers.
A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers.
The majority of nonhealing diabetic foot ulcers treated with autologous platelet-rich plasma gel can be expected to heal and Kaplan-Meier time-to-healing also was significantly different between groups.
Efficacy of Recombinant Human Epidermal Growth Factor (Regen-D 150) in Healing Diabetic Foot Ulcers: A Hospital-Based Randomized Controlled Trial
Early and regular application of the hEGH on DFUs will lead to prevention of leg amputations and would serve to act as a major treatment therapy for healing of chronic wounds.
Clinical Evaluation of Recombinant Human Platelet-Derived Growth Factor for the Treatment of Lower Extremity Ulcers
  • D. Steed
  • Medicine
    Plastic and reconstructive surgery
  • 2006
PDGF applied once daily was effective in healing chronic diabetic neurotrophic foot ulcers when used in conjunction with good wound care.
Recombinant Human Platelet‐Derived Growth Factor for Refractory Nondiabetic Ulcers: A Retrospective Series
Recombinant human platelet-derived growth factor-BB gel is an effective and well-tolerated treatment for refractory chronic ulcers other than diabetic, neuropathic ulcers.
Effectiveness and safety of autologous platelet-rich plasma therapy with total contact casting versus total contact casting alone in treatment of trophic ulcer in leprosy: An observer-blind, randomized controlled trial
PRP combined with total contact Casting accelerates the healing of trophic ulcers of leprosy and is more effective than total contact casting alone.
Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial
Treatment with SR-0379 for chronic leg ulcers was safe, well tolerated, and effective, and the clinical trial on next stage will be designed toward peptide drug development for skin ulcers.


A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.
Data from this small trial suggest that local application of rPDGF-BB may be of therapeutic benefit in accelerating the healing of chronic pressure ulcers.
Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group.
Wound debridement is a vital adjunct in the care of patients with chronic diabetic foot ulcers and for any given center, the percentage of patients who healed was greater with rhPDGF than placebo, but in general, a lower rate of healing was observed in those centers that performed less frequent debridements.
Long-Term Costs for Foot Ulcers in Diabetic Patients in a Multidisciplinary Setting
Long-term costs for diabetic foot ulcers in diabetic patients are high, mainly due to the need for increased home care and social service, but also due to costs for recurrent ulcers and new amputations.
Growth factors and wound healing: biochemical properties of growth factors and their receptors.
Peripheral Vascular Disease and Diabetes
Lower extremity arterial disease (LEAD) is clinically identified by intermittent claudica-tion and/or absence of peripheral pulses in the lower legs and feet and can be identified noninvasively before clinical manifestation.
Growth factors and wound healing: Part II. Role in normal and chronic wound healing.
Diabetic Foot Care: Financial Implications and Practice Guidelines
Diabetic foot care guidelines should be viewed by providers as recommended minimum practice levels to be adapted according to the patient's pathology, comorbidity, and abilities, and they are not intended to set a ceiling on professional excellence.
Management of diabetic midfoot ulcers.
Successful therapy for limb preservation most often included an operation combining resection of underlying osseus deformities with debridement of affected soft tissues.